“These products have the potential to reshape how Americans approach wellness by offering accessible, plant-based alternatives that complement traditional care, but realizing that potential will require more than enforcement discretion.”
By Thomas Winstanley, Edibles.com
For years, the hemp-derived CBD market has operated in a paradox: federally legal, widely available and increasingly normalized—yet lacking a clear regulatory framework that gives consumers confidence and businesses stability. The Food and Drug Administration’s (FDA) latest move to exercise enforcement discretion for certain CBD products is a meaningful step forward, underscoring how incomplete and fragile the current system remains.
At its core, FDA’s posture acknowledges that hemp-derived cannabinoids are part of Americans’ daily wellness routines. By signaling that it does not intend to enforce certain provisions of the Federal Food, Drug and Cosmetic Act against qualifying orally administered CBD products, the agency is recognizing a practical path forward, and one that is rooted in a supplement-style framework with guardrails around safety, labeling and marketing.
That matters. For the first time in decades, cannabinoids are being discussed in terms that resemble the Dietary Supplement Health and Education Act (DSHEA) of 1994. The implication is a viable lane for CBD products that aligns with how consumers already
Read full article on Marijuana Moment
